AeroFact
AeroFact Uses, Dosage, Side Effects, Food Interaction and all others data.
AeroFact is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant contains 35mg of phospholipids (including 26 mg phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine) and 0.65mg of proteins including surfactant-associated proteins B and C.
AeroFact is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency. AeroFact has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical trials. It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.
| Trade Name | AeroFact |
| Availability | Prescription only |
| Generic | Calfactant |
| Calfactant Other Names | AeroFact, Alveofact, Bovactant, Calfactant, SF-RI 1 |
| Related Drugs | beractant, Curosurf, Survanta, Infasurf, Surfaxin, lucinactant |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
AeroFact is a lung surfactant for the prophylaxis of respiratory distress syndrome in high-risk infants.
AeroFact is indicated for prophylaxis therapy to prevent respiratory distress syndrome (RDS) in premature infants <29 weeks of gestational age with low lung surfactant and at high risk for RDS. AeroFact therapy is also indicated for the treatment of respiratory distress syndrome in infants 72 hours or less of age with RDS confirmed by clinical and radiologic findings and requiring endotracheal intubation.
AeroFact is also used to associated treatment for these conditions: Respiratory Distress Syndrome
How AeroFact works
Pulmonary surfactant is an endogenous substance produced in the lungs that functions to decrease surface tension at the air:fluid interface on the alveolar surface. In premature infants with pulmonary surfactant deficiency, surface tension can increase to the point where sections of lung collapse and respiratory distress syndrome (RDS) develops. AeroFact adsorbs rapidly to the surface of the alveolar air:fluid interface and modifies surface tension to a minimum of less than 3 mN/m. It acts in a manner similar to natural lung surfactant, thus preventing or treating respiratory distress syndrome.
Toxicity
Carcinogenesis and animal reproduction studies have not been performed with calfactant. A single mutagenicity study produced a negative Ames assay. Overdose with calfactant has not yet been reported, but it is recommended that in the case of an overdose ventilation should be supported until all excess fluid is cleared from the lungs. Cyanosis, bradycardia and airway obstruction have been reported with administration of calfactant.
Food Interaction
No interactions found.Volume of Distribution
No human studies on the distribution of calfactant have been performed.
Elimination Route
AeroFact is administered directly to the lung lumen surface where it acts. No human studies on absorption have been completed.
Half Life
Half time clearance from the lung lumen was reported as 12 hours in a study of normal rabbits.
Clearance
No human studies on the metabolism and elimination of calfactant have been performed.
Elimination Route
No human studies on elimination of calfactant have been completed.
Innovators Monograph
You find simplified version here AeroFact
